Astellas US Holding, Inc. v. Federal Insurance Company

66 F.4th 1055
Court of Appeals for the Seventh Circuit·Decided May 3, 2023·No. 21-3075·Published·Cited by 7 cases

Opinion

In the

United States Court of Appeals For the Seventh Circuit

No. 21-3075 ASTELLAS US HOLDING, INC. and ASTELLAS PHARMA US, INC., Plaintiffs-Appellees,

v.

FEDERAL INSURANCE COMPANY, Defendant-Appellant.

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 1:17-cv-08220 — Franklin U. Valderrama, Judge.

ARGUED SEPTEMBER 9, 2022 — DECIDED MAY 3, 2023

Before ROVNER, HAMILTON, and SCUDDER, Circuit Judges. HAMILTON, Circuit Judge. Plaintiffs Astellas US Holding, Inc. and Astellas Pharma US, Inc. (we can treat them here as one entity, Astellas) paid the federal government $100 million to settle potential claims for violations of the federal Anti- Kickback Statute and the federal False Claims Act. The potential claims stemmed from Astellas’ contributions to so-called “patient assistance plans” to cover the costs of treatment with 2 No. 21-3075

an expensive new cancer drug. Astellas had a $10 million directors -and-officers liability insurance policy with defendant Federal Insurance Company. The many questions raised in this appeal boil down to whether Illinois public policy forbids the liability insurer from covering part of its insured’s payment to settle the federal government’s potential claims. The district court granted summary judgment for the insured, concluding that Illinois public policy does not forbid coverage of the settlement. In a thorough opinion, the court held that Federal owes Astellas the policy limit of $10 million. Astellas US Holding, Inc. v. Starr Indem. & Liab. Co., 566 F. Supp. 3d 879 (N.D. Ill. 2021).

We affirm. Under Illinois law, a party may not obtain liability insurance for genuine restitution it owes the victim of its intentional wrongdoing, but a party may obtain insurance for compensatory damages it may owe. Further, in cases of ambiguity and uncertainty, Illinois favors settlements and freedom of contract, and Federal wrote its insurance policy to try to extend insurance coverage to the very limit of what Illinois law would allow in such cases. Federal bears the burden of showing that the portion of the settlement payment for which Astellas seeks coverage is uninsurable restitution. Federal has not carried that burden with evidence that would allow a reasonable jury to decide in its favor. I. Facts for Summary Judgment & Procedural History A. Patient Assistance Plans To frame the controlling issue of Illinois insurance law, we must first provide some background about the insured’s dispute with the federal government. Drug manufacturers sponsor “patient assistance plans” to help patients obtain needed

No. 21-3075 3

medicines at affordable prices. In 2005, Congress amended the Medicare program to offer prescription drug coverage. In planning to implement the new legislation, the government raised concerns that patient assistance plans could be operated in ways that could violate the federal Anti-Kickback Statute , 42 U.S.C. § 1320a-7b, and the False Claims Act, 31 U.S.C. § 3729, by effectively rewarding doctors and patients for choosing to use particular drugs. See Special Advisory Bulletin: Patient Assistance Programs for Medicare Part D Enrollees, 70 Fed. Reg. 70623-03 (Nov. 22, 2005). The government cautioned that patient assistance plans would need to be “properly structured” to avoid illegally channeling contributions by drug makers to patients and impermissibly influencing their drug choices. Id. at 70626, 70627.

B. Astellas’ Contributions to Patient Assistance Programs In 2012 plaintiff Astellas launched Xtandi, a so-called “androgen receptor inhibitor” used to treat metastatic prostate cancer that has not responded to surgery. Initially priced at $7,800 per month, Xtandi prescriptions were to be covered by Medicare up to about $6,000 per month, leaving patients with a steep monthly co-pay of about $1,800.

When it launched Xtandi, Astellas began making contributions to a patient assistance plan run by the Chronic Disease Fund. A few months later, Astellas also started contributing to another plan run by the Patient Network Foundation. Apparently, these two funds kept running out of money. In May 2013, an Astellas marketing executive encouraged both the Chronic Disease Fund and the Patient Network Foundation to create special funds that would provide co-pay assistance for only androgen receptor inhibitors like Xtandi and just a few other medications.

4 No. 21-3075

In-house lawyers at Astellas and the two patient assistance plans and several outside law firms considered the government ’s November 2005 regulatory guidance. The lawyers blessed the plan for such narrowly targeted funds. The Chronic Disease Fund and the Patient Network Foundation then set up funds limited to helping patients who needed androgen receptor inhibitors. In July 2013, Astellas began making donations to these funds. Astellas stopped contributing to them after a few months, at the end of 2013. During those months, Astellas contributed about $27 million to the two funds. Astellas continued contributing to broader prostatecancer funds until 2016. Astellas contributed a total just shy of $130 million to the targeted and broader funds.

C. The Department of Justice Investigation and the Settlement The United States Department of Justice began investigating Astellas’ contributions to patient assistance plans for potential health care offenses. In April 2017, the Astellas marketing executive at the center of the inquiry made a “proffer” to the Department. He acknowledged that he had “hoped” and “expected” that the contributions would produce financial benefits for Astellas. But he maintained that the “primary purpose of the donations … was charitable,” and he asserted that Astellas had made no efforts to calculate “a return on investment .”

In September 2017 the Department of Justice issued a more specific and detailed Civil Investigative Demand to the same executive. One month later, Astellas agreed with the government to toll the relevant statutes of limitations for potential litigation relating to Astellas’ possible violations of the False Claims Act, the Anti-Kickback Statute, and the criminal health

No. 21-3075 5

care fraud provision of the Health Insurance Portability and Accountability Act, 18 U.S.C. § 1347.

Early in 2018, Astellas authorized its outside counsel to begin settlement negotiations. The government initially estimated its damages at approximately $460 million. As negotiations continued, the government narrowed its focus to Medicare losses attributable to Astellas’ contributions to only the narrowly focused androgen receptor inhibitor funds. The government disclosed a new, narrower damages estimate of $82 million. Applying a standard multiplier, the government sought approximately $164 million. In April 2019, Astellas settled with the government for $100 million, $50 million of which was labeled as “restitution to the United States” for tax reasons discussed below.

D. The Federal Insurance Policy and the Coverage Dispute After agreeing to the settlement, Astellas turned to several liability insurers, including Federal, to help cover portions of the $100 million settlement payment. Astellas’ directors-ando fficers excess liability insurance policy with Federal had a policy limit of $10 million. Astellas demanded the policy limit from Federal. Federal and the other insurers denied coverage.

Astellas then filed this suit for breach of the insurance contracts . Settlements with other insurers left only Federal as a defendant. On cross-motions for summary judgment, the district court ruled in favor of Astellas, concluding that Illinois law and public policy did not prohibit insurance coverage of at least $10 million of the settlement payment. 1

1In the district court, Astellas waived seeking defense costs in exchange for Federal waiving an unspecified defense relating to coverage.

6 No. 21-3075

Free access — add to your briefcase to read the full text and ask questions with AI

Astellas US Holding, Inc. v. Federal Insurance Company, 66 F.4th 1055 (7th Cir. 2023).

66 F.4th 1055 (Astellas US Holding, Inc. v. Federal Insurance Company) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related